Orca Bio Presents Data Demonstrating its Lead Investigational High-Precision Cell Therapy Orca-T Sig
– Updated data from Phase 1b/2 trials include 151 patients with acute myeloid leukemia, acute lymphocytic leukemia, myelodysplastic syndromes and other hematological malignancies –– Relapse-free survival was 87% at one year in a group of 71 patients who received the preferred conditioning regimen being used in the P...
United States Ivan Dimov Everett Meyer Joshua Murray American Society Of Hematology Marrow Transplant Research
Source: pharmiweb.com